Eisai: Eisai Lowers Sales Expectations for Leqembi Again, Citing Slow US Uptake
Eisai's new fiscal 2027 forecast for Leqembi is roughly 50% lower than its projections a year ago.
Read full article »
Eisai is a Japan-based pharmaceutical company that develops and commercializes prescription medicines and OTC drugs for the healthcare sector.
Read more